They observed previously unknown somatic mutations in the MAPK1 gene, inactivating mutations in the HLA-B gene, and mutations in EP300, FBXW7, NFE2L2, TP53 and ERBB2 in squamous cell carcinoma samples, and somatic ELF3 and CBFB mutations in adenocarcinomas. This evidence concerns the gene ERBB2 and adenocarcinoma.